VaxInnate wins $2.2M NIAID grant to develop dengue vaccine

04/5/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded VaxInnate a three-year grant worth $2.2 million to develop a recombinant tetravalent dengue vaccine using its Toll-like receptor (TLR) platform. VaxInnate's TLR technology is intended to better vaccine efficacy and immunogenicity.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC